Regenix secures Brazil deal

A TISSUE development firm spun out of a Yorkshire university has struck a deal with a Brazilian university and a related company to give it access to the £600m global heart valve market.
By The Newsroom
Published 22nd Apr 2011, 07:00 BST

Tissue Regenix has signed an agreement with the Pontifical Catholic University of Parana (PUCPR) and Cardioprotese, a business formed by lead researcher Professor Francisco da Costa.

It will have exclusive worldwide commercialisation rights, except in Brazil, to all data generated from eight years’ clinical use of decellularised human donor heart valves as valve replace- ments.

Hide Ad
Hide Ad

Tissue Regenix uses its proprietary technology, dCELL, to remove cells and other components from human and animal tissue and replace worn out or diseased body parts, without the need for anti-rejection drugs.

Antony Odell, managing director, said: “This long-term collaboration with the PUCPR and Professor da Costa is yet another example of Tissue Regenix’s strategy of seeking to expand our product pipeline more rapidly and at minimum cost and development risk to the company.

“The global heart valve market represents a major opportunity for Tissue Regenix, we look forward to commercialising the dCELL heart valve and making this product available worldwide to surgeons and patients.”

The global tissue heart valve market is estimated to reach $1.43bn (£863m) by 2016, according to Tissue Regenix, a University of Leeds spin-out.

More than 140 patients have received human donor heart valves decellularised using dCELL technology.

Related topics:BrazilYorkshire